The Role of Microparticles as a Biomarker
Withdrawn
- Conditions
- MicroparticlesAtypical Hemolytic Uremic SyndromeThrombotic Thrombocytopenic PurpuraMicroangiopathic Hemolytic Anemia
- Registration Number
- NCT02626663
- Lead Sponsor
- University of Rochester
- Brief Summary
The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with MAHA, TTP, and/or aHUS
Read More
Exclusion Criteria
- Prisoners
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Microparticle/Nanoparticle number (an absolute number) an average of 3 months Microparticle/Nanoparticle size (in nanometers or micrometers) an average of 3 months Microparticle/Nanoparticle identity (identity of cell type from which they are derived) an average of 3 months
- Secondary Outcome Measures
Name Time Method Morbidities 3 months Mortality 3 months
Trial Locations
- Locations (1)
University of Rochester Medical Center
🇺🇸Rochester, New York, United States